Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30189704 | 1.00 | CCR1 (0.33) | CCR1CCR5CCR8GRM5CYP11B2 | |
| SCHEMBL30189663 | 0.84 | ENPP2 (0.33) | CYP11B2CYP11B1 | |
| SCHEMBL21395879 | 0.84 | ENPP2 (0.33) | CYP11B2CYP11B1 | |
| SCHEMBL19782862 | 0.79 | CCR1 (0.34) | CCR1CCR5CCR8GRM5CYP11B2 | |
| SCHEMBL30189953 | 0.79 | CCR1 (0.34) | CCR1CCR5CCR8GRM5CYP11B2 | |
| SCHEMBL19782543 | 0.74 | PDE10A (0.33) | GRM5CYP11B2CYP11B1KDM4ELMNA | |
| SCHEMBL30189706 | 0.74 | PDE10A (0.33) | GRM5CYP11B2CYP11B1KDM4ELMNA | |
| SCHEMBL19783554 | 0.73 | LMNA (0.34) | GRM5CYP11B2CYP11B1KDM4ELMNA | |
| SCHEMBL30189775 | 0.71 | KDM4E (0.34) | GRM5CYP11B2CYP11B1KDM4ELMNA | |
| SCHEMBL19783559 | 0.71 | KDM4E (0.34) | GRM5CYP11B2CYP11B1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BISTOL MYERS SQUIBB COMPANY (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018013774-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292176-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, PF4 | CCR1 2972/4885CCR5 2766/4885CCR8 2189/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | CCR1 2186/4885CCR5 2573/4885CCR8 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.